Won-Gu Kang

Won-Gu Kang

Auto-generated profile, based on publicly available information

Won-Gu Kang

College of Pharmacy, Chung-Ang University, Seoul 06974, Korea

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
SYSeung-lai Yoo
Seung-lai Yoo
DKDae-Jung Kim
Dae-Jung Kim
SLSeung-Mi Lee
Seung-Mi Lee
WKWon-Gu Kang
Won-Gu Kang
SKSang-Yoon Kim
Sang-Yoon Kim
Dong-Churl SuhDong-Churl Suh
Dong-Churl Suh
This study reviews and evaluates the national drug formulary system used to improve patient access to new drugs by making reimbursement decisions for new drugs as part of the South Korean national health insurance system. The national health insurance utilizes three methods for improving patient access to costly drugs: risk-sharing agreements, designation of essential drugs, and a waiver of cost-effectiveness analysis. Patients want reimbursement for new drugs to be processed quickly to improve their access to these drugs, whereas payers are careful about listing them given the associated financial burden and the uncertainty in cost-effectiveness. However, pharmaceutical companies are advocating for drug prices above certain thresholds to maintain global pricing strategies, cover the costs of drug development, and fund future investments into research and development. The South Korean government is expected to develop policies that will improve patient access to drugs with unmet needs for broadening health insurance coverage. Simultaneously, the designing of post-listing management methods is warranted for effectively managing the financial resources of the national health insurance system.